Data Presented At The 5th Joint Triennial Congress Of ECTRIMS And ACTRIMS …TheStreet.com (press release)… marketed products, TYSABRI ® (natalizumab), AVONEX ® (interferon beta-1a) and FAMPYRA ® (prolonged-release fampridine), as well as two late…
Arthritis care announced support for new treatmentBarchester HealthcareIn 2010, Nice recommended tocilizumab as a means of treating people with arthritis if there has been an inadequate response to one or more TNF inhibitors and where rituximab has als…
University of Rochester NewsroomScientists Look to Immune System to Handle Follicular LymphomaUniversity of Rochester NewsroomIt builds on previous work by this team at the James P. Wilmot Cancer Center at the UR, in which they proved that the drug Rit…
NICE provisional OK for RoActemra in RAPharma TimesIn August 2010, NICE issued guidance TA198, which recommends RoActema as an option for people with RA if there has been an inadequate response to one or more tumour necrosis factor (TNF) inhibitors and…
Rituximab success paves way for plant produced mAbsIn-PharmaTechnologist.comiBio is expanding use of its green plant technology to biosimilar mAbs after producing rituximab using the system. Producing rituximab, marketed as Mabthera, using non-transgen…
Earnings Preview: Akamai, Advanced Micro Devices, Gilead Sciences, Biogen, CelgeneSeeking AlphaTysabri sales over $280 million would be a positive indicator, but the key question is data or FDA approvals for late-pipeline drugs like BG-12 or Daclizumab…
Abbott feiert 125 Jahre Pharmastandort LudwigshafenÄrzte ZeitungAuch klinische Projekte werden hier koordiniert. Aktuelle Beispiele sind laut Richter Phase-III Studien mit dem Krebsmittel Linifanib, dem MS-Antikörper Daclizumab sowie mit Bardoxolon g…
Takeda to withdraw sNDA for lymphoma drugPharmaceutical Business ReviewTakeda Pharmaceutical and its subsidiary the Takeda Oncology company – Millennium have made decision to withdraw the supplemental new drug application (sNDA) for the use of Velcade …
Takeda Pulls FDA Application for Expanded Use of Cancer Drug VelcadeGenetic Engineering NewsMillennium: The Takeda Oncology Company has decided to withdraw its sNDA for Velcade in combination with rituximab for the treatment of relapsed follicular lymp…
iBio announces production of biosimilar rituximab drug, shares rallyProactive Investors UKiBio (AMEX:IBIO) shares rallied around 10% Wednesday after the company announced that its proprietary iBioLaunch technology has been used to produce a functional,…